The diagnosis of GH deficiency in adult β-thalassemic patients: are two different stimulation tests necessary to improve specificity?

Emanuela D'Angelo, Daniele Sola, Nadia Mirra, Massimo Scacchi, Elena Cassinerio, Giovanna Graziadei, Mirna Solange Barrio Lower Daniele, Leila Danesi, Riccardo Pasquali

Journal: Pituitary 2025;28(3):67

PMID: 40442554

Abstract

PURPOSE

β-thalassemia major (βTM) frequently leads to endocrinological complications of chronic transfusion-induced iron overload, including growth hormone deficiency (GHD). With contrasting data on GHD in adult βTM populations, our study aimed to reevaluate the diagnosis of GHD using multiple tests and its progression over time.

METHODS

Two experimental studies were conducted in adult βTM patients to assess GH secretory status. The first study reevaluated GH secretion after two years using a GHRH plus arginine test performed initially and during follow-up. The second study applied a glucagon stimulation test to those initially diagnosed with severe GHD, comparing the results with those of a GHRH plus arginine test.

RESULTS

The first study involved 80 patients: 67 patients had normal GH secretion at the first test, confirmed in 57 of them. Of the 13 initially diagnosed with GHD, only 3 were confirmed at the second test. The second study included 91 patients: 18 of the initially identified as having severe GHD, were tested with another challenge, but only 6 confirmed severe GHD, suggesting a possible risk of overdiagnosis in initial evaluations.

CONCLUSIONS

The marked variability in GHD diagnoses among adult patients with βTM highlights the need for multiple diagnostic tests to improve accuracy and avoid unnecessary interventions. Our findings highlight the importance of reassessing GH secretory reserves with multiple tests at multiple time points, supporting a cautious approach to hormone replacement therapy, suggesting to start it only when clearly indicated.

© 2025. The Author(s).

Address: IRCCS Istituto Auxologico Italiano, Laboratory of Metabolic Research, Ospedale S. Giuseppe, Piancavallo, Oggebbio (VB), 2884, Italy. [email protected].; Department of Translational Medicine, Università del Piemonte Orientale (UPO), Novara, Italy. [email protected].; IRCCS Istituto Auxologico Italiano, Laboratory of Metabolic Research, Ospedale S. Giuseppe, Piancavallo, Oggebbio (VB), 2884, Italy.; SC Metabolic Medicine Department, Fondazione IRCCS Cà Granda Maggiore Policlinico, Milan, Italy.; SC Pediatric Emergency Department, Fondazione IRCCS Cà Granda Maggiore Policlinico, Milan, Italy.; Oncological Endocrinology, Istituto Europeo di Oncologia (IEO), Milan, Italy.; IRCCS Istituto Auxologico Italiano, Laboratory of Metabolic Research, Ospedale S. Giuseppe, Piancavallo, Oggebbio (VB), 2884, Italy.; Department of Clinical Sciences and Community Health, Dipartimento di Eccellenza 2023- 2027, Università di Milano, Milan, Italy.

Link outs

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.